Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study (Q33331466)

25 July 2017

title

Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study (English)

1 reference

25 July 2017

1 reference

C Camps

1

0 references

author name string

E N Martínez

series ordinal

2

1 reference

25 July 2017

A B Jaime

series ordinal

3

1 reference

25 July 2017

publication date

1 January 2000

1 reference

25 July 2017

1 reference

25 July 2017

volume

27

1 reference

25 July 2017

issue

1

1 reference

25 July 2017

page(s)

47-53

1 reference

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Chemotherapy of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Docetaxel in stage III and IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Gemcitabine: current status of phase I and II trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900092-6

7 January 2021

10.1016/S0169-5002(99)00092-6

Identifiers

DOI

1 reference

25 July 2017

1 reference